ARNA Financial Facts

Net loss per share allocable to common stockholders, diluted: -0.05
Collaborative agreements: 12.95M
See Full Income Statement

Deferred revenues, less current portion: 82.13M
Total liabilities and stockholders' equity: 210.25M
See Full Balance Sheet

Arena Pharmaceuticals, Inc. (ARNA) Earnings

  |   Expand Research on ARNA
Next EPS Date 2/28/17 *Est. EPS Growth Rate +54.5% *Last Qtr.
Average EPS % Beat Rate +7.1% Revenue Growth Rate +108.8% *Last Qtr.
Average % Move 1-Wk after EPS +5.7% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/7/16 Q316 -$0.05-$0.07 +$0.02$19M$13.99M N/A Details
8/8/16 Q216 -$0.11-$0.10 -$0.01$9.5M$10.44M N/A Details
5/9/16 Q116 -$0.09-$0.10 +$0.01$9.8M$9.02M N/A Details
2/29/16 Q415 -$0.13-$0.13 $0.00$7.8M$8.26M N/A Details
11/10/15 Q315 -$0.11-$0.13 +$0.02$9.1M$9.14M N/A Details
8/5/15 Q215 -$0.11-$0.14 +$0.03$9.18M$10.95M N/A Details
5/11/15 Q115 -$0.10-$0.14 +$0.04$12.3M$10.56M N/A Details
3/2/15 Q414 -$0.15-$0.12 -$0.03$9.2M$10.36M N/A Details